Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Deborah Stegner

Psychiatry Phoenix, AZ Medical Doctor

NPI 1033265715 CMS profile 962251

4545 E Chandler Blvd Ste 308, Phoenix, AZ 85048

Open in the dashboard

General payments

$6,478

349 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Deborah Stegner of Phoenix, AZ is reported in the CMS Open Payments database as having received $6,478 across 349 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,544 84
2024 General $1,714 95
2023 General $1,038 48
2022 General $832 48
2021 General $896 51
2020 General $258 14
2019 General $195 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deborah Stegner
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Deborah Stegner were reported at $1,544. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Deborah Stegner Psychiatry median Middle half National median
2019 $195 $184 $59–$605 $163
2020 $258 $119 $36–$372 $114
2021 $896 $143 $43–$576 $132
2022 $832 $153 $50–$590 $149
2023 $1,038 $170 $56–$651 $160
2024 $1,714 $179 $57–$673 $164
2025 $1,544 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,348 105 payments
  2. Supernus Pharmaceuticals, Inc. $636 29 payments
  3. Alkermes, Inc. $519 18 payments
  4. Lundbeck LLC $507 32 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $469 28 payments
  6. Otsuka America Pharmaceutical, Inc. $468 22 payments
  7. Vanda Pharmaceuticals Inc. $451 19 payments
  8. Axsome Therapeutics, Inc. $385 12 payments
  9. Almatica Pharma LLC $343 17 payments
  10. ITI, Inc. $235 11 payments
  11. Other $1,116 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,277 345 payments
  2. Education $200 4 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $1,097 80 payments
  2. LYBALVI Cns $519 18 payments
  3. LYBALVI Cns $519 18 payments
  4. LYBALVI Cns $494 17 payments
  5. LYBALVI Cns $494 17 payments
  6. Qelbree $485 18 payments
  7. TRINTELLIX $469 28 payments
  8. FANAPT $451 19 payments
  9. REXULTI $432 28 payments
  10. VRAYLAR Neuroscience $412 34 payments
  11. Other $2,983 144 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

260

Median for Psychiatry: 574

Drug cost

$40,839

Median for Psychiatry: $27,624

Branded share of claims

38.1%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Auvelity Dextromethorphan Hbr/Bupropion Brand 23 $24,081
Trintellix Vortioxetine Hydrobromide Brand 11 $13,159
Bupropion Xl Bupropion Hcl Brand 38 $861
Propranolol Hcl Er Propranolol Hcl Brand 16 $715
Mirtazapine Generic 17 $387
Duloxetine Hcl Generic 11 $378
Buspirone Hcl Generic 30 $276
Alprazolam Generic 25 $237
Aripiprazole Generic 11 $226
Clonazepam Generic 17 $201

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $529
$529 — —
REXULTI
  • Lundbeck LLC $156
  • Otsuka America Pharmaceutical, Inc. $100
$256 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $250
$250 — —
LYBALVI
  • Alkermes, Inc. $159
$159 — —
Auvelity
  • Axsome Therapeutics, Inc. $109
$109 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

349 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record